Actuate Therapeutics, Inc. Stock-Based Compensation
Actuate Therapeutics, Inc. (ACTU) reported Stock-Based Compensation of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.34M, a 15.10% decline year-over-year.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.36M, a 20.56% increase year-over-year.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.54M, a 29.38% increase year-over-year.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.80M, a 218.14% increase year-over-year.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.05M, a 202.97% increase from fiscal 2024.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.00M, a 371.22% increase from fiscal 2023.
- Actuate Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $423.54K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-14 | $2.70M 10-Q · filed 2026-08-14 | $4.24M derived: sum of 3 quarters · filed 2026-08-14 | $6.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-14 | $2.90M derived: sum of 2 quarters · filed 2026-05-14 | $4.70M derived: sum of 3 quarters · filed 2026-05-14 | $6.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.34M derived: sum of 2 quarters · filed 2026-03-26 | $4.92M derived: sum of 3 quarters · filed 2026-08-14 | $6.05M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.38M derived: sum of 2 quarters · filed 2026-08-14 | $4.50M 10-Q · filed 2025-11-13 | $5.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.58M 10-Q · filed 2026-08-14 | $2.70M 10-Q · filed 2026-08-14 | $3.90M derived: sum of 3 quarters · filed 2026-08-14 | $4.46M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-14 | $2.32M derived: sum of 2 quarters · filed 2026-05-14 | $2.88M derived: sum of 3 quarters · filed 2026-05-14 | $2.97M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.76M derived: sum of 2 quarters · filed 2026-03-26 | $1.85M derived: sum of 3 quarters · filed 2026-03-26 | $2.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $565.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $656.00K derived: sum of 2 quarters · filed 2025-11-13 | $804.21K 10-Q · filed 2025-11-13 | $926.26K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $90.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $238.22K 10-Q · filed 2025-08-14 | $360.27K derived: sum of 3 quarters · filed 2025-08-14 | $515.50K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $148.21K 10-Q · filed 2025-05-15 | $270.26K derived: sum of 2 quarters · filed 2025-05-15 | $425.48K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $122.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $277.28K derived: sum of 2 quarters · filed 2025-03-13 | $423.54K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $155.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $301.49K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $146.26K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |